modified-DEP
Phase 3Small molecule
modified-DEP is one of 10 small molecule programs targeting Histiocytosis. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Histiocytosis
#DrugCompanyPhaseTrials
1Jakafi
IncyteApproved
Vepesid
AAvyxa
Approved
Decadron
AAspen Global Incorporated
Approved
Leustatin
EMD SeronoApproved
Alkeran
AApotex Inc.
Approved
Zelboraf
CConrado Roberto Hoffmann Filho
Phase 2
ELA026
EElectra Therapeutics Inc.
Phase 3
modified-DEP
TThe First Affiliated Hospital of Soochow University
Phase 3
Prevymis
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
EBV-TCR-T Cells
FFujian Cancer Hospital
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Histiocytosis1 trial
Modified DEP Regimens for the Treatment of Hemophagocytic Lymphohistiocytosis
Not yet recruiting·TThe First Affiliated Hospital of Soochow University·Phase 4·NCT06504030·20 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for modified-DEP. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details